SwePub
Sök i LIBRIS databas

  Utökad sökning

(WFRF:(Dorum A.))
 

Sökning: (WFRF:(Dorum A.)) > (2016) > Niraparib Maintenan...

  • Mirza, M. R.Nordic Soc Gynecol Oncol, Denmark; Copenhagen University Hospital, Denmark (författare)

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

  • Artikel/kapitelEngelska2016

Förlag, utgivningsår, omfång ...

  • MASSACHUSETTS MEDICAL SOC,2016
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-133383
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-133383URI
  • https://doi.org/10.1056/NEJMoa1611310DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies|Tesaro; Amgen; Genentech; Roche; AstraZeneca; Myriad Genetics; Merck; Gradalis; Cerulean; Vermillion; ImmunoGen; Pfizer; Bayer; Nu-Cana BioMed; INSYS Therapeutics; GlaxoSmithKline; Verastem; Mateon Therapeutics; Pharmaceutical Product Development; Clovis Oncology; Janssen/Johnson Johnson; Eli Lilly; Merck Sharp Dohme
  • BACKGROUND Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought to evaluate the efficacy of niraparib versus placebo as maintenance treatment for patients with platinum-sensitive, recurrent ovarian cancer. METHODS In this randomized, double-blind, phase 3 trial, patients were categorized according to the presence or absence of a germline BRCA mutation (gBRCA cohort and non-gBRCA cohort) and the type of non-gBRCA mutation and were randomly assigned in a 2: 1 ratio to receive niraparib (300 mg) or placebo once daily. The primary end point was progression-free survival. RESULTS Of 553 enrolled patients, 203 were in the gBRCA cohort (with 138 assigned to niraparib and 65 to placebo), and 350 patients were in the non-gBRCA cohort (with 234 assigned to niraparib and 116 to placebo). Patients in the niraparib group had a significantly longer median duration of progression-free survival than did those in the placebo group, including 21.0 vs. 5.5 months in the gBRCA cohort (hazard ratio, 0.27; 95% confidence interval [CI], 0.17 to 0.41), as compared with 12.9 months vs. 3.8 months in the non-gBRCA cohort for patients who had tumors with homologous recombination deficiency (HRD) (hazard ratio, 0.38; 95% CI, 0.24 to 0.59) and 9.3 months vs. 3.9 months in the overall non-gBRCA cohort (hazard ratio, 0.45; 95% CI, 0.34 to 0.61; P amp;lt; 0.001 for all three comparisons). The most common grade 3 or 4 adverse events that were reported in the niraparib group were thrombocytopenia (in 33.8%), anemia (in 25.3%), and neutropenia (in 19.6%), which were managed with dose modifications. CONCLUSIONS Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity. (Funded by Tesaro; ClinicalTrials.gov number, NCT01847274.)

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Monk, B. J.University of Arizona, AZ USA; Creighton University of Phoenix, AZ USA; Arizona Oncology Associates, AZ USA (författare)
  • Herrstedt, J.University of Southern Denmark, Denmark (författare)
  • Oza, A. M.University of Toronto, Canada (författare)
  • Mahner, S.Arbeitsgemeinschaft Gynakol Onkol, Germany; University of Munich, Germany (författare)
  • Redondo, A.GEICO, Spain; Hospital University of La Paz, Spain (författare)
  • Fabbro, M.French Investigator Grp Ovarian and Breast Cancer GIN, France; Institute Cancer Montpellier, France (författare)
  • Ledermann, J. A.UCL, England; UCL, England (författare)
  • Lorusso, D.Ist Nazl Tumori, Italy (författare)
  • Vergote, I.Luxembourg Gynecol Oncology Grp, Belgium; University of Leuven, Belgium (författare)
  • Ben-Baruch, N. E.Kaplan Medical Centre, Israel (författare)
  • Marth, C.AGO Austria, Austria; Medical University of Innsbruck, Austria (författare)
  • Madry, R.Central and Eastern European Gynecol Oncology Grp, Poland; Uniwersytet Medical Poznaniu, Poland (författare)
  • Christensen, R. D.University of Southern Denmark, Denmark (författare)
  • Berek, J. S.Stanford Comprehens Cancer Institute, CA USA (författare)
  • Dorum, A.Oslo University Hospital, Norway (författare)
  • Tinker, A. V.British Columbia Cancer Agency, Canada (författare)
  • du Bois, A.Kliniken Essen Mitte, Germany (författare)
  • Gonzalez-Martin, A.GEICO, Spain; MD Anderson Cancer Centre Madrid, Spain (författare)
  • Follana, P.GINECO, France; Centre Antoine Lacassagne, France (författare)
  • Benigno, B.Northside Hospital, GA USA (författare)
  • Rosenberg, PerLinköpings universitet,Avdelningen för kliniska vetenskaper,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US(Swepub:liu)perro95 (författare)
  • Gilbert, L.McGill University, Canada (författare)
  • Rimel, B. J.Cedars Sinai Medical Centre, CA USA (författare)
  • Buscema, J.Arizona Oncology Associates, AZ USA (författare)
  • Balser, J. P.Veristat, MA USA (författare)
  • Agarwal, S.Tesaro, MA USA (författare)
  • Matulonis, U. A.Dana Farber Cancer Institute, MA 02115 USA (författare)
  • Nordic Soc Gynecol Oncol, Denmark; Copenhagen University Hospital, DenmarkUniversity of Arizona, AZ USA; Creighton University of Phoenix, AZ USA; Arizona Oncology Associates, AZ USA (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:New England Journal of Medicine: MASSACHUSETTS MEDICAL SOC375:22, s. 2154-21640028-47931533-4406

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy